Free tool
FAERS Monitor: Medical Air, Usp
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 205765 or its brand name (Medical Air, Usp, Medical Air). Reports on generic versions are filed under their own applications.
Reports
22
Serious
20
91% of reports
Hospitalization
6
Death reported
2
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- cardiac arrest3
- drug interaction3
- atrial fibrillation2
- blood pressure decreased2
- cyanosis2
- dystonia2
- oxygen saturation decreased2
- polyuria2
- product quality issue2
- sinus tachycardia2
- underdose2
- acidosis1
- alanine aminotransferase increased1
- anaesthetic complication cardiac1
- anaphylactic reaction1
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 2 |
| 2005 | 1 |
| 2006 | 2 |
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 1 |
| 2011 | 1 |
| 2012 | 1 |
| 2014 | 3 |
| 2016 | 1 |
| 2017 | 1 |
| 2021 | 3 |
| 2023 | 3 |
| 2026 | 1 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,137 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| anaesthetic complication cardiac | 1 | 14073.6 | 2043.5 | 3,466 |
| polyuria | 2 | 233.6 | 62.3 | 260 |
| sinus tachycardia | 2 | 134.7 | 35.9 | 149 |
| acidosis | 1 | 125.1 | 18.4 | 30 |
| cyanosis | 2 | 121.6 | 32.4 | 134 |
| dystonia | 2 | 98.6 | 26.3 | 108 |
| cardiac arrestSignal | 3 | 34.7 | 12.1 | 68 |
| oxygen saturation decreased | 2 | 34.0 | 9.1 | 35 |
| blood pressure decreased | 2 | 28.8 | 7.7 | 30 |
| underdose | 2 | 26.2 | 7.0 | 27 |
| atrial fibrillation | 2 | 19.6 | 5.2 | 19 |
| drug interactionSignal | 3 | 18.1 | 6.3 | 33 |
| anaphylactic reaction | 1 | 17.3 | 2.5 | 3 |
| alanine aminotransferase increased | 1 | 15.6 | 2.3 | 3 |
| product quality issue | 2 | 14.1 | 3.8 | 13 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.